Synchron raises $200M to advance its brain-computer interface for paralysis

Synchron Raises $200 Million to Advance Brain-Computer Interface

Synchron has secured $200 million in a Series D funding round to expand its operations and speed up the commercialization of its non-surgical brain-computer interface (BCI) designed for people with paralysis.

Investment and Participation

Double Point Ventures led the round.
Existing investors included Arch Ventures, Khosta Ventures, Bezos Expeditions, NTI, and Metis.
Additional participants were the Australian National Reconstruction Fund, T.Rx Capital, Qatar Investment Authority, K5 Global, Protocol Labs, and IQT.

This funding increases the total capital raised by the New York-based medtech company to $345 million.

BCI Industry Momentum

The brain-computer interface sector is gaining traction recently:

Precision Neuroscience, another BCI developer focused on paralysis, partnered with SCI Ventures, backed by the Christopher & Dana Reeve Foundation, to develop its Layer 7 Cortical Interface.
A recent study showed that Science Corp.’s PRIMA BCI retinal implant partially restored vision for people with severe age-related macular degeneration.

"Synchron has reeled in another $200 million in a series D round — cash the company said it will use to expand operations and accelerate commercialization of its non-surgical brain-computer interface for people with paralysis."

Author’s summary: Synchron's recent $200 million funding boosts its mission to commercialize nonsurgical brain-computer interfaces, reflecting growing momentum in the BCI field for paralysis and vision restoration.

Fierce Biotech — 2025-11-07

Synchron Raises $200 Million to Advance Brain-Computer Interface

Investment and Participation

BCI Industry Momentum

More News